induction treatment with VAD or TAD, treatment arm was included as a covariate. To compare our results with those previously published, we also evaluated the prognostic value of donor availability for the VAD and TAD subgroups separately, as well as in subgroups according to ISS stage (I vs II vs III), β -2 microglobulin (β-2 M; ≤ 3 vs > 3 mg/l) and presence or absence of deletion 13
(determined by FISH and/or by karyotyping). 14 Kaplan-Meier curves were generated to illustrate differences between subgroups. All reported P values are 2-sided and have not been adjusted for multiple testing, and a significance level alpha = 0 .05 was used.
The best response as determined by CR was 43% for patients with a donor and 38% for patients without a donor (p= 0.41). The 8-year and 10-year PFS were 25% and 17% for patients with a donor and 18% and 16% for the patients without a donor ( Figure 2A ). RMST 10y was 6 months longer in the donor group (95% CI -5 to 16, P=0.29), which was not statistically significant. RMST 10y was also not significantly different between donor and no-donor in the subgroups of VAD patients and TAD patients. ß-2 > 3 was associated with an 11 months lower RMST 10y (95% CI 0 to 22, P=0.04), but in the DvnD comparison no significant difference in PFS was found for patients with low or high ß-2 M.
This was also apparent for ISS stage and the presence or absence of deletion 13 either determined by FISH (available for 61 % of no donor and 57 % of donor patients) or determined by karyotyping (available for 82 % of no donor and 83 % of donor patients).
The 8-year and 10 year OS were 47% and 42% for patients with a donor and 43% and 33% for the patients without a donor ( Figure 2B ). RMST 10y was 4 months longer in the no-donor group (95% CI -15 to 7, P=0.46). This non-significant 4.1 months longer RMST 10y for OS in the no-donor patients was also observed within the subgroups of VAD patients and TAD patients, both P=0.6. ß-2 M > 3 was associated with a 17 months lower RMST 10y (95% CI 6 to 28, P=0.003), but the difference in RMST 10y between donor and no-donor patients in each of the low or high ß-2 M subgroups was less than one months (P=0.9). There was also no significant difference in PFS within the subgroups according to ISS and the presence or absence of deletion 13. The cumulative incidence of non-relapse mortality at 96 months after Auto-SCT was 16% in the donor group versus 3% in the no donor group (p< 0.001) and the cumulative incidence of relapse at 96 months was 77% in the no-donor arm versus 55% in the donor arm (p=0.001), see Figures 3A and 3B.
We also compared the outcome of the 99 patients who received their allocated Allo-SCT with the 115 patients who started with their allocated maintenance therapy after Auto-SCT. Response status (ORR, CR and VGPR) was comparable in both groups. The 8-year and 10-year PFS tr were 27% and 21% for the Auto/Allo-SCT patients and 15% and 10% for the Auto/maintenance patients ( Figure 2C ). A nonsignificant 10-months increase in RMST 10y (95% CI -1 to 21, P=0.08) was observed in the Auto/Allo-SCT patients. While RMST 10y was longer 17 months in the patients treated with VAD (P=0.04), it was only 6 months longer in the TAD patients (P=0.47). Furthermore, an increase in RMST 10y of 25 months in the Auto/Allo-SCT patients was observed in patients without deletion 13 (P=0.009).
The 8-year and 10-year OS tr were 50% and 42% for Allo-SCT patients and 43% and 29% for the Auto/Maintenance patients ( Figure 2D ). A non-significant increase in RMST 10y of 3 months (95% CI -9 to 15, P=0.65) was observed in the Auto/Allo-SCT patients. Thalidomide was not associated with improved outcome. ß-2 M > 3 predicted for reduced survival (P=0.02). However no benefit for Allo-SCT as compared to maintenance was found in this patient category. Neither ISS nor deletion 13 had a significant impact on OStr.
With the longest follow-up (median 113 months since Auto-SCT) of published studies until now we found no benefit for Allo-SCT as part of first line therapy on PFS and OS. The positive Graft versus Myeloma effect as demonstrated by the significantly reduced incidence of relapse in the donor arm did not compensate for the higher TRM. (figure 3) As in our previous analysis there was a trend for prolonged PFS in the patients treated with the allocated Allo-SCT, however due to late relapses this did not lead to a significant benefit when compared to patients receiving maintenance following Auto-SCT. The absence of a benefit in our updated study may be due to better outcome for the no-donor group as compared with the Italian and EBMT studies, while the outcome with regard to PFS and OS of patients with a donor seemed rather similar. Our study was initiated later , so that bortezomib and lenalidomide could be routinely given to patients with relapsed disease. It may be that the availability of these new anti-myeloma agents for relapse explain the comparable survival of the patients who did receive their allocated therapy, although the PFS curves diverge after 30 months in favour of the Allo-SCT group. There were 6 patients with progressive disease after 8 years. None of them have died, with follow up between 3 and 25 months later A major question is whether in this era of effective MM strategies Allo-SCT should be completely abandoned or whether it could still be an option for patients with high risk features like 17p deletion or patients with an early first relapse. 15 In case this is explored alternative strategies are essential to allow effective and safe post Allo-SCT strategies to prevent both TRM, early relapse and initiation of specific graft versus myeloma effects. 
Figure legends
Legend to figure 1
Design of the study and patient flow 
Legend to figure 3A
The cumulative incidence of relapse at 96 months was 77% in the no-donor arm versus 55% in the donor arm (p=0.001).
Legend to figure 3B
The cumulative incidence of non-relapse mortality at 96 months was 3% in the no-donor arm versus 16% in the donor arm (p<0.001).
